Last point seems most significant........but the whole thing appears to be 'setting the stage' for some serious 'developments' in the next 6 months imo.
“As Executive Vice President and Chief Commercia lOfficer,Vince has played a leading role in two large dermatology transactions with a combined valuation of US$7.8bn, including the recent sale of dermatology Anacor to Pfizer for US$5.2bn.”
"Botanix is uniquely positioned and poised for success with its pipeline of novel therapies that have the potential to meet many unmet patient needs. The Company is also way ahead of the curve with its delivery technology, PermetrexTM,a highly elegant formulation with considerable potential across the broader dermatology space".
Ann: Dermatology Industry Leader Joins Botanix, page-4
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.3¢ |
Change
-0.008(1.97%) |
Mkt cap ! $684.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 37.0¢ | $1.697M | 4.526M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 411276 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 335833 | 19 |
View Market Depth
| Last trade - 14.53pm 04/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |